Purpose Cardiac amyloidosis exists in two predominant forms called acquired monoclonal immunoglobulin light-chain (AL) and transthyretin-related (ATTR). Their differentiation is a real diagnostic challenge for treatment management and prognosis of patient. Magnetic resonance (MR) imaging is increasingly used to aid in the diagnosis of cardiac amyloidosis on the basis of characteristic appearances on late Gadolinium enhancement (LGE) but cannot distinguish ATTR and Al forms. Several series have showed that scintigraphy using bone 99mTc-bisphosphonate tracers preferentially bind ATTR versus AL myocardial deposit. Our aim was to use 18F-Sodium Fluoride (18F-NaF) positron emission tomography (PET) bone tracer in hybrid PET/MR imaging to aid in both the diagnosis of cardiac amyloidosis and differentiation of ATTR and AL forms within a single scan. Methods Consecutive patients with biopsy-proven ATTR or AL cardiac amyloidosis and as many healthy control subjects were included. All patients underwent simultaneous PET/MR (BiographTM mMR, Siemens) scans after IV injection of 370MBq of 18F-NaF. The selected data were reconstructed using a 3D breath-hold Dixon MR attenuation correction map. MR protocol included LGE sequences, pre- and post-contrast T1 mapping. Maximal target-to-background ratio (TBRmax) was recorded, defined as maximal myocardial FDG uptake (SUVmax) corrected for mean right atrium blood pool activity. Mean TBRmax in ATTR, AL and controls were compared using a Student t-test. The institutional review board approved the study and all patients gave written informed consent. Results Eighteen patients (61.3 ± 10.5 yo, 12 M/6F) were prospectively recruited (6 ATTR, 3 AL and 9 controls). All amyloid patients had characteristic LGE appearances. Mean TBRmax were respectively 1.29 ± 0.31, 0.77 ± 0.06 and 0.68 ± 0.03 in ATTR, AL and control subjects. Mean TBRmax was significantly higher in ATTR than in AL patients ( P = 0.028) and in controls ( P = 0.0001). Mean TBRmax was significantly higher in AL patients than in controls ( P = 0.046). A TBRmax threshold of 0.85 appeared to differentiate all patients as having ATTR amyloidosis. There was no significant difference in terms of pre-contrast ( P = 0.48) and post-contrast T1 mapping ( P = 0.57) between ATTR and AL patients. Conclusion These results showed the potential of 18F-NaF PET/MR to diagnose cardiac amyloidosis and to differentiate ATTR and AL forms, confirming our preliminary published results (Trivieri et al. JACC 2016)